Augmentation of current antidepressant (SSRI) with ziprasidone (40 mg/d to 160 mg/d) vs augmentation of current antidepressant (SSRI) with placebo or continue on SSRI monotherapy
Depressive symptoms · treatment‐resistant depression in adults
1 finding from 1 review
- Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 199 participantsModerate